Viola W. Zhu

9.0k citations

83 papers · 2.6k indexed · h-index 30

Pulmonary and Respiratory Medicine top 1%
- Lung Cancer Treatments and Mutations 75
- Advanced Breast Cancer Therapies 7
Oncology top 1%
- Lung Cancer Research Studies 26
- Colorectal Cancer Treatments and Studies 24
Cancer Research top 2%
- Cancer Genomics and Diagnostics 19
Pathology and Forensic Medicine top 5%
Molecular Biology top 10%
- Cancer therapeutics and mechanisms 9
Surgery
- Cholangiocarcinoma and Gallbladder Cancer Studies 6
Endocrinology, Diabetes and Metabolism
- Thyroid Cancer Diagnosis and Treatment 6

Co-authors: Sai‐Hong Ignatius Ou Misako Nagasaka Alexa B. Schrock Siraj M. Ali Thanyanan Reungwetwattana Samuel J. Klempner Vincent A. Miller Ying Liang
Cited by: Pulmonary and Respiratory Medicine Oncology Cancer Research
Partner nations: United States South Korea France

In The Last Decade

Viola W. Zhu

82 papers receiving 2.6k citations

Peers

Countries citing papers authored by Viola W. Zhu

Since Specialization

Citations

This map shows the geographic impact of Viola W. Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Viola W. Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Viola W. Zhu more than expected).

Fields of papers citing papers by Viola W. Zhu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Viola W. Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Viola W. Zhu. The network helps show where Viola W. Zhu may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Viola W. Zhu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Viola W. Zhu Line = papers co-authored together Viola W. Zhu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	1256MO Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours B. Besse,Alexander Drilon,BC Cho,D. Ross Camidge,Joel W. Neal,C-C. Lin,S.V. Liu,M. Nagasaka,S.C-H. Kao,Eudald Felip,Anthonie J. van der Wekken,C.-C. Lin,J.R. Bauman,S. Gadgeel,Manoj Samant,Jiayu Shen,Yun Sun,Viola W. Zhu,Vipul Upadhyay,W. Marston Linehan	2024	6
2	78TiP Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study Benjamin Besse,Melissa L. Johnson,S-H.I. Ou,Shirish M. Gadgeel,A. Spira,Jung‐Yaw Lin,E. Felip,Anthonie J. van der Wekken,Antonio Calles,M.J. de Miguel,D. Ross Camidge,Yasir Y. Elamin,G. Lopes,Stephen V. Liu,Jessica R. Bauman,Daniel Haggstrom,G. Riley,Henry E. Pelish,Viola W. Zhu,A. Drilon	2022	1
3	1654P Updated ARROW data: Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC) Min Hu,V. Subbiah,Aaron S. Mansfield,Matthew H. Taylor,M.H.H. Schuler,Viola W. Zhu,Julien Hadoux,Giuseppe Curigliano,Lori J. Wirth,Elena Garralda,Douglas R. Adkins,Y. Godbert,M-J. Ahn,P. Cassier,Byoung Chul Cho,C-C. Lin,Teresa Barata,Alena Zalutskaya,Astrid Scalori,Marcia S. Brose	2022	2
4	Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001 Caroline E. McCoach,Christian Rolfo,Alexander Drilon,Mario E. Lacouture,Benjamin Besse,Kōichi Goto,Viola W. Zhu,Daniel S.W. Tan,Stephanie Farajian,Laura A. Potter,Jennifer Kherani,Victoria Soldatenkova,Elizabeth Olek,Catherine E. Muehlenbein,Keunchil Park	2022	27
5	Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis Viola W. Zhu,Joseph J. Zhao,Yanfei Gao,Nicholas Syn,Shannon Zhang,Sai‐Hong Ignatius Ou,Kenneth A. Bauer,Misako Nagasaka	2021	33
6	Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC Shannon Zhang,Misako Nagasaka,Viola W. Zhu,Sai‐Hong Ignatius Ou	2021	74
7	EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study Guangjian Yang,Jun Li,Haiyan Xu,Yaning Yang,Lu Yang,Fei Xu,Bing Xia,Viola W. Zhu,Misako Nagasaka,Yan Yang,LI Ya-pin,Weini Qiu,Jianming Ying,Sai‐Hong Ignatius Ou,Yan Wang	2020	75
8	<p>Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases</p> Viola W. Zhu,Misako Nagasaka,Takafumi Kubota,Kunil Raval,Natasha Robinette,Octavio A. Armas,Wajd N. Al‐Holou,Sai‐Hong Ignatius Ou	2020	8
9	Identification of Novel CDH1-NRG2α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing Sai‐Hong Ignatius Ou,Joanne Xiu,Misako Nagasaka,Bing Xia,Shannon Zhang,Qing Zhang,Jeffrey Swensen,David Spetzler,W. Michael Korn,Viola W. Zhu,Stephen V. Liu	2020	6
10	1291P Hypersensitivity reactions (HR) to selpercatinib in RET fusion+ non-small cell lung cancer (NSCLC) patients (pts) following immune checkpoint inhibition (CPI) Caroline E. McCoach,D.S.W. Tan,Benjamin Besse,Keiko Goto,Viola W. Zhu,Christian Rolfo,Stephanie Farajian,Laura A. Potter,Jennifer Kherani,Victoria Soldatenkova,Elizabeth Olek,P. Lee,K. Park	2020	6
11	Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer W. Marston Linehan,Stephen V. Liu,Caroline E. McCoach,Viola W. Zhu,Aaron C. Tan,Satoshi Yoda,Jennifer Peterson,Andrew Do,Kylie Prutisto-Chang,Ibiayi Dagogo‐Jack,Lecia V. Sequist,Lori J. Wirth,Jochen K. Lennerz,Aaron N. Hata,Mari Mino–Kenudson,Valentina Nardi,S.-H.I. Ou,Daniel Shao-Weng Tan,Justin F. Gainor	2020	161
12	1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins) Greg J. Riely,Joel W. Neal,D. Ross Camidge,Alexander I. Spira,Zofia Piotrowska,Leora Horn,Daniel B. Costa,Anne S. Tsao,Jay Patel,Shirish M. Gadgeel,Lyudmila Bazhenova,Viola W. Zhu,Howard West,Tarek Mekhail,Ryan D. Gentzler,D. Nguyen,Veronica Bunn,Shu Jin,Zhichun Feng,Pasi A. Jänne	2020	15
13	Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC Misako Nagasaka,Viola W. Zhu,Sun Min Lim,Michael N. Greco,Fengying Wu,Sai‐Hong Ignatius Ou	2020	138
14	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors W. Marston Linehan,Adam J. Schoenfeld,Viola W. Zhu,Beow Y. Yeap,Emily Chin,Marguerite Rooney,Andrew J. Plodkowski,Subba R. Digumarthy,Ibiayi Dagogo‐Jack,Justin F. Gainor,Sai‐Hong Ignatius Ou,Gregory J. Riely,Alice T. Shaw	2019	54
15	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis Mark M. Awad,Giulia C. Leonardi,Sasha Kravets,Suzanne E. Dahlberg,Alexander Drilon,Sinéad Noonan,D. Ross Camidge,Sai‐Hong Ignatius Ou,Daniel B. Costa,Shirish M. Gadgeel,Conor Steuer,Patrick M. Forde,Viola W. Zhu,Yoko Fukuda,Jeffrey W. Clark,Pasi A. Jänne,Tony Mok,Lynette M. Sholl,Rebecca S. Heist	2019	76
16	P1.01-127 Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions Gregory J. Riely,Joel W. Neal,D. Ross Camidge,Alexander I. Spira,Zofia Piotrowska,Leora Horn,Daniel B. Costa,Anne S. Tsao,Jyoti D. Patel,S. Gadgeel,Lyudmila Bazhenova,Viola W. Zhu,Howard West,Sylvie Vincent,Ji‐Min Zhu,Shu Jin,S. Zhang,S. Li,Pasi A. Jänne	2019	3
17	Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC W. Marston Linehan,Viola W. Zhu,Adam J. Schoenfeld,Beow Y. Yeap,Ashish Saxena,Lorin A. Ferris,Ibiayi Dagogo‐Jack,Anna F. Farago,Angela Marie Taber,Anne M. Traynor,Smitha Menon,Justin F. Gainor,Jochen K. Lennerz,Andrew J. Plodkowski,Subba R. Digumarthy,Sai‐Hong Ignatius Ou,Alice T. Shaw,Gregory J. Riely	2018	54
18	Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors Alexa B. Schrock,Viola W. Zhu,Wen-Son Hsieh,Russell W. Madison,Ben Creelan,Jeffrey Silberberg,Dan Costin,Anjali Bharne,Ioana Bonta,Thangavijayan Bosemani,Petros Nikolinakos,Jeffrey S. Ross,Vincent A. Miller,Siraj M. Ali,Samuel J. Klempner,Sai‐Hong Ignatius Ou	2018	107
19	OA09 Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer S.‐H.I. Ou,Byoung Chul Cho,D. Kim,Alexander Drilon,J. Lee,W. Marston Linehan,Viola W. Zhu,Myung‐Ju Ahn,D. Ross Camidge,Shanna Stopatschinskaja,Jialiang Liu,J. Jean Cui,David M. Hyman,Robert C. Doebele,Alice T. Shaw	2018	3
20	TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling Viola W. Zhu,Daya Upadhyay,Alexa B. Schrock,Kyle Gowen,Siraj M. Ali,Sai‐Hong Ignatius Ou	2016	33

About Viola W. Zhu

Viola W. Zhu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research, having authored 83 papers that have together received 2.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (75 papers), Lung Cancer Research Studies (26 papers), Colorectal Cancer Treatments and Studies (24 papers), Cancer Genomics and Diagnostics (19 papers), Cancer therapeutics and mechanisms (9 papers), Advanced Breast Cancer Therapies (7 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers) and Thyroid Cancer Diagnosis and Treatment (6 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.1k citations), Oncology (1.7k citations) and Cancer Research (646 citations). Viola W. Zhu has collaborated with scholars based in United States, South Korea and France. Frequent co-authors include Sai‐Hong Ignatius Ou, Misako Nagasaka, Alexa B. Schrock, Siraj M. Ali, Thanyanan Reungwetwattana, Samuel J. Klempner, Vincent A. Miller, Ying Liang, Shannon Zhang and Alexander Drilon.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact